IgM Mesangial Deposition Predicts Relapses of Adult-Onset Minimal Change Disease

Cheng-Wen Yang  
Far Eastern Memorial Hospital

Fan-Yu Chen  
Taipei Veterans General Hospital

Fu-Pang Chang  
Taipei Veterans General Hospital

Yang Ho  
Taipei Veterans General Hospital

An-Hang Yang  
Taipei Veterans General Hospital

Der-Cherng Tamg  
Taipei Veterans General Hospital

Chih-Yu Yang  (cyyang3@vghtpe.gov.tw)  
National Yang-Ming University School of Medicine  https://orcid.org/0000-0001-9899-3159

Research article

Keywords: adult-onset, minimal change disease, IgM mesangial deposition, relapse

DOI: https://doi.org/10.21203/rs.3.rs-76984/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

**Background:** Immunoglobulin M (IgM) mesangial deposition in pediatric minimal change disease (MCD) has been reported to be associated with steroid dependence and poor renal outcomes. However, the evidence regarding the impact of IgM mesangial deposition on the treatment responses or outcomes in adult-onset MCD is lacking.

**Methods:** In this retrospective cohort study, 37 adult patients with MCD received kidney biopsy from January 2010 to May 2020. According to IgM mesangial deposition by immunofluorescence microscopy, the patients were divided into two groups (12 patients with positive IgM deposition; 25 patients with negative IgM deposition). We analyzed the clinical features, the dosage of immunosuppressive agents, and the response to treatment for two years between the two groups.

**Results:** Regarding the clinical symptoms, the dosage of immunosuppressive treatment, and the time to remission, there was no statistically significant difference between the two groups. Compared to the negative IgM group, the frequency of relapses was significantly higher in the positive IgM group within the two-year follow-up period (the negative IgM group 0.25 episodes/year; the positive IgM group 0.75 episodes/year, \( p = 0.029 \)). Furthermore, multivariate linear regression revealed that the positivity of IgM mesangial deposition is independently associated with the frequency of relapses (regression coefficient B 0.450, 95% CI 0.116-0.784, \( p = 0.010 \)).

**Conclusions:** Our findings indicated that adult-onset MCD patients with IgM mesangial deposition have a high risk of relapses. Therefore, prolonged and combined immunosuppressive therapy with close follow-up may be considered in MCD adults with IgM mesangial deposition.

Introduction

Minimal change disease (MCD) is the absence of glomerular changes, tubular injury, interstitial fibrosis, or sclerosis under light microscopy. The immunofluorescence analysis classically showed negative staining, but some reveal immunoglobulin M (IgM) positive [1]. IgM is a serum antibody and serves as a primary activator for the complement cascade. Because IgM is a large molecule, which is difficult to diffuse, it may deposit in the tissue [2]. The diffuse granular global mesangial IgM deposition may affect renal glomeruli, like IgA nephropathy, so many pediatric MCD studies focused on the predictors of kidney function or treatment response with IgM deposition [3–5]. Such IgM deposition was observed in 11.9% of children and 4.3% of adults in an Indian study [6].

MCD with a positive IgM mesangial deposition was more likely to evolve into focal segmental glomerulosclerosis (FSGS) than those without IgM deposition in the pediatric population [7]. Besides, IgM deposition has been considered as a transitional factor between MCD and FSGS [8]. In addition, IgM deposition is also found in other subtypes of idiopathic nephrotic syndrome [4]. A study showed that idiopathic nephrotic syndrome children with a positive IgM mesangial deposition had a worse response to therapy [6].
A positive IgM mesangial deposition has been reported to be associated with steroid dependence and worse renal outcomes in the pediatric population [2, 5, 9]. On the other hand, previous studies only focused on the histopathology and natural history in adult-onset MCD with positive IgM mesangial deposition [4, 10, 11]. The clinical significance of a positive IgM mesangial deposition in adult-onset MCD is unknown. Therefore, our study aims to compare the treatment response in adult-onset MCD with or without IgM mesangial deposition, including the time to partial remission, complete remission, time to the first relapse, and frequency of relapses.

Methods

Patients

The protocol of this study was approved by the Institutional Review Board of Taipei Veterans General Hospital, Taipei, Taiwan. The protocol conformed with the ethical guidelines of the Helsinki Declaration. The need for informed consent was waived because of the retrospective nature of the study. We enrolled patients who were diagnosed as MCD by renal biopsy at the Taipei Veterans General Hospital from January 2010 to May 2020. Eighty-one samples were purely MCD, without significant tubulointerstitial, glomerular, and vascular lesions. As shown in Fig. 1, we excluded patients with age less than 18 years old, follow up for less than one year, previous immunosuppressive treatment, systemic diseases (such as systemic lupus erythematosus, rheumatoid arthritis, diabetes mellitus, and prior renal transplant), and missing data. All of 37 patients had been examined for IgM mesangial deposition by immunofluorescence microscopy.

Study protocol and subjects

Nephrotic syndrome is characterized by overt proteinuria (more than 3.5 g/ 24 h), hypoalbuminemia (less than 2.5 g/dL), hyperlipidemia, and edema. Hematuria is defined by urinalysis (urine red blood cell (RBC) more than 3/high-power field (HPF)). We collected serial urine protein to creatinine ratio (UPCR), urine RBC, serum albumin, serum immunoglobulin, lipid profiles, blood pressure, and serum creatinine. The estimated glomerular filtration rate (eGFR) was estimated according to the Chronic Kidney Disease Epidemiology Collaboration formula [12]. IgM mesangial deposition (grade from 1+ to 3+) is categorized as the positive IgM group. Partial remission (PR) is defined as the reduction of UPCR between 0.3 and 3.5 mg/dL with stable serum creatinine. Complete remission (CR) is defined as a UPCR of less than 0.3 mg/dL with normal serum creatinine. A relapse is defined as UPCR of more than 3.5 mg/dL after CR, according to the Kidney Disease Improving Global Outcomes (KDIGO) guideline [13].

Immunosuppressive therapy was initiated after biopsy, and the majority of them used prednisolone. Adjuvant immunosuppressants include cyclosporine (CsA), mycophenolic acid (MPA), and cyclophosphamide (CYC). Because this is a retrospective study, the decision on dosages and types of immunosuppressive agents was at the discretion of each attending nephrologist.

Statistical analysis
Chi-square analysis or Fisher's exact test was used for comparisons of categorical variables as appropriate. Continuous variables were compared by Student's t-test. For linear regression analysis, the frequency of relapses was set as the dependent variable, and IgM-associated variables were used as independent variables. In subgroup analysis, patients were divided into two subgroups according to their mean value to examine the subgroup difference. The reference line in Fig. 2 is the mean value plus one standard deviation. SPSS version 19.0 for Windows (SPSS Inc., Chicago, Illinois, USA) was used for all statistical analyses. All probabilities were two-tailed, and a \( p \)-value of less than 0.05 was considered to be statistically significant.

Results

Baseline characteristics of the study subjects

Clinical characteristics of 37 patients with MCD are listed in Table 1. The average age of patients is 39.7 years old. There were no statistically significant differences in blood pressure, lipid profile, serum albumin, serum IgM, renal function, proteinuria, and hematuria between the two groups. Upon electron microscopic examination, all enrollees have the effacement of the podocyte foot processes, without significant tubulointerstitial, glomerular, and vascular lesions by light microscopy. In immunohistology, IgM positivity is defined as diffuse IgM deposits in the mesangial area. The intensity of IgM was 1 + in five patients, 2 + in five patients, and 3 + in two patients. Among the positive IgM group, one patient also had positive IgG, two patients had positive complement 1q, and one patient had positive complement 3 (all in the positive IgM group). In patients of the negative IgM group, all immunofluorescent examinations showed negative findings.
Table 1
Demographic characteristics and clinical features in adult-onset minimal change disease on light microscopy.

| Parameters                          | All        | IgM (+)    | IgM (-)    | p-Value |
|------------------------------------|------------|------------|------------|---------|
| Patient number (n)                 | 37         | 12         | 25         |         |
| Age (year)                         | 39.7 ± 16.5| 38.5 ± 14.9| 40.3 ± 17.6| 0.755   |
| Male gender (n; %)                 | 16; 43.2   | 5; 41.7    | 11; 44.0   | 0.893   |
| Body weight (kg)                   | 65.6 ± 13.0| 64.7 ± 11.5| 66.0 ± 13.8| 0.777   |
| Blood pressure                     |            |            |            |         |
| Systolic blood pressure (mmHg)     | 129.4 ± 23.6| 134.9 ± 28.3| 126.8 ± 21.1| 0.332   |
| Diastolic blood pressure (mmHg)    | 82.1 ± 14.9 | 86.8 ± 18.0 | 79.8 ± 12.8 | 0.178   |
| Antihypertensive drug use (n; %)   | 14; 37.8   | 3; 25.0    | 11; 44.0   | 0.306   |
| Lipid profile                      |            |            |            |         |
| Cholesterol (mg/dL)                | 405.0 ± 153.3| 380.6 ± 116.1| 415.7 ± 168.2| 0.535   |
| Triglyceride (mg/dL)               | 188.3 ± 122.6| 197.8 ± 83.6 | 183.4 ± 126.6 | 0.726   |
| Low density lipoprotein-cholesterol (mg/dL) | 290.6 ± 123.8| 258.7 ± 104.7| 304.5 ± 131.9| 0.427   |
| High density lipoprotein-cholesterol (mg/dL) | 82.9 ± 39.6 | 54 ± 25.2 | 92.6 ± 39.8 | 0.152   |
| Statin use (n; %)                  | 22; 59.5   | 7; 58.3    | 15; 60.0   | 1.000   |
| Laboratory data at biopsy          |            |            |            |         |
| Serum Creatinine (mg/dL)           | 1.0 ± 0.6  | 0.8 ± 0.2  | 1.0 ± 0.7  | 0.250   |
| eGFR (mL/min/1.73 m²)              | 97.8 ± 29.9| 107.1 ± 20.4| 93.4 ± 33.0| 0.195   |
| Serum Albumin (g/dL)               | 2.2 ± 0.9  | 2.4 ± 1.1  | 2.2 ± 0.8  | 0.507   |
| UPCR (mg/dL)                       | 8.2 ± 4.9  | 7.3 ± 4.3  | 8.6 ± 5.2  | 0.465   |
| Urine RBC (/HPF)                   | 8.4 ± 16.4 | 12.3 ± 27.8 | 6.4 ± 6.2  | 0.482   |
| Serum IgM (mg/dL)                  | 164.8 ± 117.7| 201.9 ± 171.9| 147.0 ± 78.8| 0.188   |
| Serum IgM/IgG (%) | 36.6 ± 52.7 | 50.6 ± 88.6 | 29.8 ± 20.7 | 0.267 |

*p < 0.05. Values are expressed as mean ± standard deviation. Abbreviations: IgM, immunoglobulin M; eGFR, estimated glomerular filtration rate; RBC, red blood cells; UPCR, urine protein to creatinine ratio; HPF, high power field.

**Immunosuppressive agent regimens**

A summary of immunosuppressive treatment is listed in Supplementary Table 1. Two patients (both the negative IgM group) have been follow-up for only one year, and others have been follow-up for more than two years. The average follow-up duration is 23.5 months. They all received immunosuppressive therapy after the biopsy. Prednisolone is the first-line immunosuppressant in this study. Only two patients received parenteral pulse methylprednisolone therapy (one patient belongs to the negative IgM group; another is in the positive IgM group). Three patients never used steroids (one patient received CsA therapy in the positive IgM group; one patient received CsA in the negative IgM group; another patient received CYC in the negative IgM group). The dosage of immunosuppressive treatment was not significantly different between the two groups.

**Treatment responses**

Response to therapy is presented in Table 2. The time to partial remission, complete remission, and first relapse after treatment were not significantly different between the two groups. Five patients did not achieve complete remission (three patients in the negative IgM group, 12.0%; two patients in the positive IgM group, 16.7%, *p = 1.000*). The frequency of relapses was significantly different between these two groups (0.25 ± 0.37 episodes/year in the negative IgM group vs. 0.75 ± 0.59 episodes/year in the positive IgM group, *p = 0.029*) during two years.
Table 2
The treatment response in adult-onset minimal change disease on light microscopy.

| Parameters                                             | All  | IgM (+) | IgM (-) | p    |
|--------------------------------------------------------|------|---------|---------|------|
| Patient number (n)                                     | 37   | 12      | 25      |      |
| Time to partial remission after treatment (days)       | 34.0 ±75.0 | 51.8 ±125.9 | 25.4 ±30.7 | 0.487 |
| Time to complete remission after treatment or last follow-up (days) | 152.2 ±230.9 | 154.7 ±269.9 | 151.0 ±215.8 | 0.965 |
| No complete remission during two years (n; %)          | 5; 13.5 | 2; 16.7 | 3; 12.0 | 1.000 |
| Time to first relapse after treatment (days)           | 357.1 ±179.8 | 347.6 ±167.8 | 365.4 ±200.9 | 0.856 |
| Frequency of relapses during two years (episodes/year) | 0.41 ±0.50 | 0.75 ±0.59 | 0.25 ±0.37 | 0.029* |

*p < 0.05. Values are expressed as mean ± standard deviation. Abbreviation: IgM, immunoglobulin M.

Univariate and multivariate linear regression analysis of the frequency of relapses were presented in Tables 3 and 4. Two factors (IgM deposition in immunofluorescence microscopy and prednisolone daily dose/body weight during two years) are associated with frequency of relapses (IgM deposition, regression coefficient B 0.464, 95% CI 0.146–0.781, p = 0.006; and prednisolone daily dose, regression coefficient B 1.660, 95% CI 0.07–3.25, p = 0.041) by univariate analysis. Further multivariate linear regression analysis disclosed that only IgM deposition is independently associated with the frequency of relapses (regression coefficient B 0.450, 95% CI 0.116–0.784, p = 0.010).
Table 3
Univariate linear regression analysis of the frequency of relapses in adult-onset minimal change disease on light microscopy.

| Parameters                                      | Coefficient B | 95% CI       | p-Value |
|------------------------------------------------|---------------|--------------|---------|
| IgM deposition on immunofluorescence microscopy | 0.464         | 0.146–0.781  | 0.006*  |
| Serum IgM                                      | 0.001         | 0.000-0.002  | 0.179   |
| Serum IgM/IgG                                   | 0.002         | -0.001-0.005 | 0.129   |
| Prednisolone daily dose/body weight during two years | 1.660         | 0.070–3.250  | 0.041*  |
| Cyclosporine daily dose/body weight during two years | 0.077         | -0.456-0.611 | 0.750   |
| Mycophenolic acid daily dose/body weight during two years | -0.075        | -0.216-0.067 | 0.191   |
| Cyclophosphamide daily dose/body weight during two years | 0.475         | -2.775-3.724 | 0.594   |

*p < 0.05. Abbreviations: IgM, immunoglobulin M; CI, confidence interval.

Table 4.
Multivariate linear regression analysis of the frequency of relapses in adult-onset minimal change disease on light microscopy.

| Parameters                                      | Coefficient B | 95% CI       | p-Value |
|------------------------------------------------|---------------|--------------|---------|
| IgM deposition on immunofluorescence microscopy | 0.450         | 0.116-0.784  | 0.010*  |
| Prednisolone therapy daily dose/body weight during two years | 0.060         |              | 0.060   |

*p < 0.05. Abbreviations: IgM, immunoglobulin M; CI, confidence interval.

Subgroup analysis

We divided patients into two subgroups according to mean (Mean age was 40 years; mean eGFR was 97.8 mL/min/1.73 m²; mean cholesterol level was 405 mg/dL) and clinical definition (the presence of nephrotic-range proteinuria; the presence of microscopic hematuria). Figure 2 showed the change in the frequency of relapses in different subgroups by mean and one standard deviation (SD). The reference line (0.905 episodes/year) in Fig. 2 is the mean value plus one SD of the frequency of relapses for all patients. It demonstrated that some subgroups crossed the reference line, including older age group (Age ≥
40 years), male group, lower eGFR group (eGFR < 97.8 mL/min/1.73 m²), hypercholesterolemia group (cholesterol ≥ 405 mg/dL), hypoalbuminemia group (serum albumin < 2.5 g/dL), proteinuria groups (both UPCR < 3.5 mg/dL and UPCR ≥ 3.5 mg/dL), and no microscopic hematuria group (urine RBC < 3 /HPF).

**Discussion**

Several pediatric studies examined the clinical symptoms, steroid response, relapses, and renal outcomes in idiopathic nephrotic syndrome children with or without IgM mesangial deposition. We, for the first time, investigated the predictive value of IgM mesangial deposition on patient outcomes in newly-diagnosed MCD adults. In our adult-onset MCD cohort, the multivariate linear regression analysis revealed that IgM deposit positivity is independently associated with a significantly higher frequency of relapses. Besides, further subgroup analysis showed that patients who developed MCD at the age of > 40 years old were associated with a higher frequency of relapses than those < 40 years old.

Previous studies showed a significantly higher mean serum IgM level in children with positive IgM deposition [14, 15]. In our study, there is a trend of increased IgM and IgM/IgG ratio in the positive IgM group but did not achieve the statistical significance, probably due to the small sample size. Previous studies showed the IgM deposition increased risks of chronic kidney disease (CKD) and end-stage kidney disease in children for more than ten years of follow-up [2, 5], showing the clinical implication of IgM positivity in MCD. Our study did not examine renal failure because of the reserved eGFR and the relatively short follow-up period in our cohort, but further research of IgM positivity on long-term renal outcomes in adult-onset MCD is warranted.

On the other hand, in our study, the frequency of relapses is more common in men with IgM deposition by our subgroup analysis. In an MCD study composed of both children and adults, gender is not a determinant of renal function progression [4]. Nevertheless, it has been reported that the renal function of males declined more rapidly than females in nondiabetic CKD [16].

In previous studies, children with IgM deposition were more likely to have hypertension [2, 17] and hematuria [5, 17]. There was no difference in blood pressure, lipid profile, renal function, hematuria, and proteinuria in MCD with or without IgM deposition [1, 6, 18], which were also noted in our study. Besides, according to our subgroup analysis, a higher frequency of relapses is more common in patients with lower eGFR < 97.8 mL/min/1.73 m², serum albumin < 2.5 g/dL group, serum cholesterol ≥ 405 mg/dL, the presence of nephrotic-range proteinuria, and the absence of microscopic hematuria. In accordance with our study, a previous study also demonstrated that microscopic hematuria is a favorable sign [19].

There are no randomized controlled trials on the treatment of MCD with IgM deposition. Corticosteroids constitute the mainstay of therapy in MCD. The prevalence of steroid resistance in idiopathic nephrotic syndrome patients with positive IgM deposition is inconclusive, varying from 0 to 52% [20]. Several studies showed a higher steroid dependence in MCD children with IgM deposition [2, 9]. Conversely, IgM deposition was not related to increased steroid resistance and steroid dependence in other pediatric...
studies [1, 17]. In our adult MCD cohort, there was also no difference between steroid resistance between patients with or without IgM deposition. Furthermore, in terms of time to partial remission, time to complete remission, and time to the first relapse after treatment, there was no difference between these two groups.

Adjuvant immunosuppressive therapy includes CsA, CYC, MPA, and levamisole, etc. [21]. Several studies evaluated the effect of adjuvant immunosuppressive therapy in idiopathic nephrotic syndrome [22–24]. CsA and CYC significantly reduced relapse risk compared with prednisolone alone in the frequent relapsing idiopathic nephrotic syndrome in pediatric patients [22]. In a study of idiopathic nephrotic syndrome, CsA and CYC are both effective and well-tolerated in adults and children [23]. CYC has more side effects, such as bone marrow suppression, gonadal toxicity, infection, seizure, malignancies, etc. [24]. Therefore, a study showed the CsA potentially indicated as first-line therapy in steroid-resistant nephrotic syndrome [25]. The patients with positive IgM deposition have a better response to CsA than CYC [3]. Combined CsA and prednisolone can be more effective than prednisolone alone in MCD children with positive IgM deposition [26]. No significant difference in response to non-corticosteroid treatment was found between the MCD patients with or without IgM positivity [1, 2, 17, 27]. Our sample size is too small to evaluate the effect of adjuvant immunosuppressive therapy.

There are some limitations in the present study. First, the sample size is small, so we cannot evaluate the subgroup analysis optimally. Second, there is a relatively short follow-up period, so we did not evaluate further renal function. Third, this is only a retrospective study, and the decision on dosages and types of immunosuppressive agents was at the discretion of each attending nephrologist. However, the average dosages of immunosuppressive agents are similar between patients with and without IgM mesangial deposition, as shown in Supplementary Table 1.

In conclusion, our novel findings indicated that newly diagnosed MCD adults with IgM mesangial deposition are more likely to experience disease relapses than those without, particularly in patients with older age, male, hypoalbuminemia, lower eGFR, the presence of nephrotic-range proteinuria, or the absence of microscopic hematuria. Therefore, immunosuppressive agents may be tapered slowly with close follow-up in these patients. Besides, MCD adults with a positive IgM deposition might be benefited from combined immunosuppressive therapy than prednisolone alone, as suggested in previous pediatric studies [22, 23, 26].

Declarations

Ethics approval and consent to participate

The protocol of this study was approved by the Institutional Review Board of Taipei Veterans General Hospital, Taipei, Taiwan. The protocol conformed with the ethical guidelines of the Helsinki Declaration. The need for informed consent was waived because of the retrospective nature of the study.

Consent for publication
Not applicable.

**Availability of data and materials**

All data are fully available without restriction.

**Competing interests**

The authors have no conflicts of interest to declare.

**Funding**

This work was supported financially for research purposes by the “Yin Yen-Liang Foundation Development and Construction Plan” of the School of Medicine, National Yang-Ming University, Taipei, Taiwan (107F-M01-0504), the Ministry of Science and Technology, Taipei, Taiwan (MOST 109-2314-B-010-053-MY3), grants from the Taipei Veterans General Hospital, Taipei, Taiwan (VGHUST107-G5-3-3 and VGHUST109-V5-1-2), and the “Center for Intelligent Drug Systems and Smart Bio-devices (IDS²B)” from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan. The funders have no role in study design, data collection, analysis, and interpretation, or in writing of the manuscript.

**Authors’ contributions**

Study design: C.-W. Y. and C.-Y. Y.; Study conduct: C.-W. Y., F.-Y. C., F.-P. C., H. Y., A.-H. Y., D.-C. T. and C.-Y. Y.; Data collection: C.-W. Y., F.-Y. C., F.-P. C., H. Y.; Data analysis: C.-W. Y. and C.-Y. Y.; Data interpretation: C.-W. Y. and C.-Y. Y.; Drafting manuscript: C.-W. Y.; Revising manuscript content: C.-Y. Y.; Approving final version of manuscript: C.-W. Y., F.-Y. C., F.-P. C., H. Y., A.-H. Y., D.-C. T. and C.-Y. Y.

**Acknowledgments**

Not applicable.

**References**

1. Vintar Spreitzer M, Vizjak A, Ferluga D, Kenda RB, Kersnik Levart T: Do C1q or IgM nephropathies predict disease severity in children with minimal change nephrotic syndrome? Pediatr Nephrol 2014, 29(1):67-74.

2. Al Romaili DM, Al-Hussain TO, Awad HS, Saadeh SA, Al-Hassoun IA, Al-Shareef TA: Clinical significance of IgM deposition in pediatric minimal change disease. Int J Pediatr Adolesc Med 2019, 6(4):146-150.

3. Swartz SJ, Eldin KW, Hicks MJ, Feig DI: Minimal change disease with IgM+ immunofluorescence: a subtype of nephrotic syndrome. Pediatr Nephrol 2009, 24(6):1187-1192.
4. Myllymaki J, Saha H, Mustonen J, Helin H, Pasternack A: IgM nephropathy: clinical picture and long-term prognosis. *Am J Kidney Dis* 2003, **41**(2):343-350.

5. Mubarak M, Kazi JI, Shakeel S, Lanewala A, Hashmi S, Akhter F: Clinicopathologic characteristics and steroid response of IgM nephropathy in children presenting with idiopathic nephrotic syndrome. *APMIS* 2011, **119**(3):180-186.

6. Vanikar AV, Kanodia KV, Patel RD, Suthar KS, Patel HV, Gumber MR, Trivedi HL: IgM nephropathy in India: a single centre experience. *Indian J Pediatr* 2012, **79**(8):1025-1027.

7. Zeis PM, Kavazarakis E, Nakopoulos L, Moustaki M, Messaritaki A, Zeis MP, Nicolaidou P: Glomerulopathy with mesangial IgM deposits: long-term follow up of 64 children. *Pediatr Int* 2001, **43**(3):287-292.

8. Brugnano R, Del Sordo R, Covarelli C, Gnappi E, Pasquali E: IgM nephropathy: is it closer to minimal change disease or to focal segmental glomerulosclerosis? *J Nephrol* 2016, **29**(4):479-486.

9. Ji-Yun Y, Melvin T, Sibley R, Michael AF: No evidence for a specific role of IgM in mesangial proliferation of idiopathic nephrotic syndrome. *Kidney Int* 1984, **25**(1):100-106.

10. Mubarak M, Naqvi R, Kazi J, Shakeel S: Immunoglobulin M nephropathy in adults: a clinicopathological study. *Iran J Kidney Dis* 2013, **7**(3):214-219.

11. Singhai AM, Vanikar AV, Gopani KR, Kanodia KV, Patel RD, Suthar KS, Patel HV, Gumber MR, Shah PR, Trivedi HL: Immunoglobulin M nephropathy nephropathy in adults and adolescents in India: a single-center study of natural history. *Indian J Pathol Microbiol* 2011, **54**(1):3-6.

12. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T *et al*.: A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009, **150**(9):604-612.

13. Chapter 5: Minimal-change disease in adults. *Kidney International Supplements* 2012, **2**(2):177-180.

14. Helin H, Mustonen J, Pasternack A, Antonen J: IgM-associated glomerulonephritis. *Nephron* 1982, **31**(1):11-16.

15. Border WA: Distinguishing minimal-change disease from mesangial disorders. *Kidney Int* 1988, **34**(3):419-434.

16. Neugarten J, Acharya A, Silbiger SR: Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. *J Am Soc Nephrol* 2000, **11**(2):319-329.

17. Al-Eisa A, Carter JE, Lirenman DS, Magil AB: Childhood IgM nephropathy: comparison with minimal change disease. *Nephron* 1996, **72**(1):37-43.

18. Shakeel S, Mubarak M, Kazi JI, Lanewala A: The prevalence and clinicopathological profile of IgM nephropathy in children with steroid-resistant nephrotic syndrome at a single centre in Pakistan. *J Clin Pathol* 2012, **65**(12):1072-1076.

19. Saha H, Mustonen J, Pasternack A, Helin H: Clinical follow-up of 54 patients with IgM-nephropathy. *Am J Nephrol* 1989, **9**(2):124-128.

20. Mubarak M, Kazi JI: IgM nephropathy revisited. *Nephrourol Mon* 2012, **4**(4):603-608.
21. van Husen M, Kemper MJ: New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome. *Pediatr Nephrol* 2011, **26**(6):881-892.

22. Hodson EM, Willis NS, Craig JC: Non-corticosteroid treatment for nephrotic syndrome in children. *Cochrane Database Syst Rev* 2008(1):CD002290.

23. Ponticelli C, Edefonti A, Ghio L, Rizzoni G, Rinaldi S, Gusmano R, Lama G, Zacchello G, Confalonieri R, Altieri P *et al*: Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. *Nephrol Dial Transplant* 1993, **8**(12):1326-1332.

24. Latta K, von Schnakenburg C, Ehrich JH: A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. *Pediatr Nephrol* 2001, **16**(3):271-282.

25. Plank C, Kalb V, Hinkes B, Hildebrandt F, Gefeller O, Rascher W, Arbeitsgemeinschaft fur Padiatrische N: Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome—a randomized controlled multicentre trial by the Arbeitsgemeinschaft fur Padiatrische Nephrologie. *Pediatr Nephrol* 2008, **23**(9):1483-1493.

26. Gregory MJ, Smoyer WE, Sedman A, Kershaw DB, Valentini RP, Johnson K, Bunchman TE: Long-term cyclosporine therapy for pediatric nephrotic syndrome: a clinical and histologic analysis. *J Am Soc Nephrol* 1996, **7**(4):543-549.

27. Geier P, Roushdi A, Skalova S, Vethamuthu J, Weiler G, Feber J: Is cyclophosphamide effective in patients with IgM-positive minimal change disease? *Pediatr Nephrol* 2012, **27**(12):2227-2231.